Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Hemab Therapeutics Holdings, Inc.
13G
COAG · 423494103
|
7.1% |
8/14/2026
Event 6/30/2026
|
|||
| Avoro Capital Advisors LLC | 4.1% | ||||
| Avoro Ventures LLC | 2.9% | ||||
| Behzad Aghazadeh | 7.1% | ||||
|
Arrowhead Pharmaceuticals, Inc.
13G/A
ARWR · 04280A100
|
9.6% |
8/14/2026
Event 6/30/2026
|
|||
| Avoro Capital Advisors LLC | 9.6% | ||||
| Behzad Aghazadeh | 9.6% | ||||
|
Avalo Therapeutics, Inc.
13G/A
AVTX · 05338F306
|
4.4% |
8/14/2026
Event 6/30/2026
|
|||
| Avoro Capital Advisors LLC | 4.4% | ||||
| Behzad Aghazadeh | 4.4% | ||||
|
Scribe Therapeutics, Inc.
13D
SCTX · 811033109
|
16.4% |
7/30/2026
Event 7/24/2026
|
|||
| Avoro Capital Advisors LLC | 13.8% | ||||
| Avoro Ventures LLC | 2.6% | ||||
| Aghazadeh Behzad | 16.4% | ||||
|
Centessa Pharmaceuticals plc
13G/A
CNTA · 152309100
|
7.4% |
5/15/2026
Event 3/31/2026
|
|||
| Avoro Capital Advisors LLC | 7.4% | ||||
| Behzad Aghazadeh | 7.4% | ||||
|
Soleno Therapeutics Inc
13G/A
SLNO · 834203309
|
4.5% |
5/15/2026
Event 3/31/2026
|
|||
| Avoro Capital Advisors LLC | 4.5% | ||||
| Behzad Aghazadeh | 4.5% | ||||
|
Xenon Pharmaceuticals, Inc.
13G/A
XENE · 98420N105
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Avoro Capital Advisors LLC | 6.3% | ||||
| Behzad Aghazadeh | 6.3% | ||||
|
Damora Therapeutics, Inc.
13G
DMRA · 36322Q206
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Avoro Capital Advisors LLC | 6.3% | ||||
| Behzad Aghazadeh | 6.3% | ||||
|
Whitehawk Therapeutics, Inc.
13D/A
WHWK · 00032Q104
|
20.0% |
5/14/2026
Event 5/12/2026
|
|||
| Avoro Capital Advisors LLC | 20.0% | ||||
| Avoro Ventures LLC | 4.1% | ||||
| Behzad Aghazadeh | 20.0% | ||||
|
uniQure N.V.
13G/A
QURE · N90064101
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Avoro Capital Advisors LLC | 9.9% | ||||
| Behzad Aghazadeh | 9.9% | ||||
|
Avidity Biosciences, Inc.
13G/A
RNAM · 05370A108
|
5.5% |
2/17/2026
Event 12/31/2025
|
|||
| Avoro Capital Advisors LLC | 5.5% | ||||
| Behzad Aghazadeh | 5.5% | ||||
|
Celcuity Inc.
13G
CELC · 15102K100
|
6.7% |
2/17/2026
Event 12/31/2025
|
|||
| Avoro Capital Advisors LLC | 6.7% | ||||
| Behzad Aghazadeh | 6.7% | ||||
|
Definium Therapeutics, Inc.
13G
DFTX · 24477V105
|
5.1% |
2/17/2026
Event 12/31/2025
|
|||
| Avoro Capital Advisors LLC | 5.1% | ||||
| Behzad Aghazadeh | 5.1% | ||||
|
Monte Rosa Therapeutics, Inc.
13G/A
GLUE · 61225M102
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Avoro Capital Advisors LLC | 0% | ||||
| Behzad Aghazadeh | 0% | ||||
|
Amicus Therapeutics, Inc.
13G/A
FOLD · 03152W109
|
4.9% |
11/14/2025
Event 9/30/2025
|
|||
| Avoro Capital Advisors LLC | 4.9% | ||||
| Behzad Aghazadeh | 4.9% | ||||
|
MoonLake Immunotherapeutics
13G/A
MLTX · 61559X104
|
3.2% |
11/14/2025
Event 9/30/2025
|
|||
| Avoro Capital Advisors LLC | 3.2% | ||||
| Behzad Aghazadeh | 3.2% | ||||
|
Structure Therapeutics Inc.
13G
GPCR · 86366E106
|
9.4% |
11/14/2025
Event 9/30/2025
|
|||
| Avoro Capital Advisors LLC | 9.4% | ||||
| Aghazadeh Behzad | 9.4% | ||||
|
Blueprint Medicines Corp
13G/A
BPMC · 09627Y109
|
0.6% |
8/14/2025
Event 6/30/2025
|
|||
| Avoro Capital Advisors LLC | 0.6% | ||||
| Behzad Aghazadeh | 0.6% | ||||
|
Tourmaline Bio, Inc.
13G/A
TRML · 89157D105
|
10.0% |
8/14/2025
Event 6/30/2025
|
|||
| Avoro Capital Advisors LLC | 10.0% | ||||
| Behzad Aghazadeh | 10.0% | ||||
|
Biocryst Pharmaceuticals Inc
13G/A
BCRX · 09058V103
|
4.2% |
5/15/2025
Event 3/31/2025
|
|||
| Avoro Capital Advisors LLC | 4.2% | ||||
| Behzad Aghazadeh | 4.2% | ||||
|
Vera Therapeutics, Inc.
13G/A
VERA · 92337R101
|
8.9% |
2/14/2025
Event 12/31/2024
|
|||
| Avoro Capital Advisors LLC | 8.9% | ||||
| Behzad Aghazadeh | 8.9% | ||||